loading
전일 마감가:
$0.94
열려 있는:
$0.8801
하루 거래량:
7,109
Relative Volume:
0.04
시가총액:
$37.61M
수익:
-
순이익/손실:
$-8.53M
주가수익비율:
-3.6196
EPS:
-0.2434
순현금흐름:
$-12.75M
1주 성능:
-11.01%
1개월 성능:
-11.01%
6개월 성능:
-30.63%
1년 성능:
-5.27%
1일 변동 폭
Value
$0.8701
$0.9196
1주일 범위
Value
$0.87
$0.9899
52주 변동 폭
Value
$0.63
$3.23

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name
명칭
Estrella Immunopharma Inc
Name
전화
(510) 318-9098
Name
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
Name
직원
0
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ESLA's Discussions on Twitter

ESLA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ESLA
Estrella Immunopharma Inc
0.881 37.61M 0 -8.53M -12.75M -0.2434
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스

pulisher
Jun 07, 2025

Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN

Jun 07, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com

Jun 05, 2025
pulisher
Jun 04, 2025

Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire

Jun 03, 2025
pulisher
May 30, 2025

Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

May 30, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World

May 05, 2025
pulisher
Apr 24, 2025

ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com

Apr 24, 2025
pulisher
Mar 05, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace

Mar 05, 2025
pulisher
Feb 22, 2025

Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian

Feb 21, 2025
pulisher
Feb 20, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net

Feb 20, 2025
pulisher
Feb 19, 2025

Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 18, 2025
pulisher
Dec 16, 2024

Estrella Immunopharma regains Nasdaq compliance - Investing.com

Dec 16, 2024
pulisher
Nov 25, 2024

Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com

Nov 25, 2024
pulisher
Nov 14, 2024

Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St

Nov 14, 2024
pulisher
Nov 11, 2024

Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™

Nov 11, 2024
pulisher
Nov 07, 2024

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks

Nov 07, 2024
pulisher
Oct 31, 2024

Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com

Oct 31, 2024
pulisher
Oct 09, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™

Oct 09, 2024
pulisher
Oct 03, 2024

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®

Oct 03, 2024
pulisher
Sep 27, 2024

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire

Sep 27, 2024

Estrella Immunopharma Inc (ESLA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
자본화:     |  볼륨(24시간):